DR. TINGTING TAN M.D. PH.D. NPI 1669627238

NPI Information

  • NPI: 1669627238
  • Provider Name: DR. TINGTING TAN, M.D. PH.D.
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 1601 AVOCADO AVE
    NEWPORT BEACH, CA
    ZIP 92660
  • Phone: (949) 763-2204

Map and Directions

Get Directions

NPI Details

DR. Tingting Tan, M.D. PH.D. is a hematology and oncology internal medicine in Newport Beach, CA with 28 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Tingting Tan, M.D. PH.D. NPI is 1669627238. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

1601 AVOCADO AVE
NEWPORT BEACH, CA
ZIP 92660-798
Phone: (949) 763-2204

The NPI 1669627238 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
  • Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
  • Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
  • Unclassified drugs (HCPCS:J3490)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
  • Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)

The enumeration date for this NPI number is 11/24/2008 and was last updated on 12/8/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & OncologyA109526CALIFORNIAYes

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.